{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:27:41Z","timestamp":1791548861496,"version":"4.3.4"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2023,9,27]]},"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>The rising prevalence of myopia is a concern in ophthalmology, with myopic choroidal neovascularisation (m-CNV) significantly affecting vision. However, long-term outcomes of m-CNV management have been unsatisfactory, leading to high recurrence rates. These studies aim to identify risk factors for m-CNV recurrence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Comprehensive review followed a pre-registered plan in the International Prospective Register of Systematic Reviews (PROSPERO). The search strategy used various databases including PubMed, Cochrane Library, Embase, Scopus and ScienceDirect using the keywords \u2018Myopic Choroidal Neovascularization\u2019, \u2018Recurrence\u2019 and \u2018Risk\u2019. Eligible studies were identified and analysed based on predetermined criteria. This study was registered on PROSPERO (CRD4202343461).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The systematic review included three retrospective studies investigating risk factors associated with m-CNV recurrence. These factors are: (1) requiring three or more injections for initial disease control, (2) older age, (3) larger myopic macular neovascularisation, (4) juxtafoveal CNV, (5) larger height of hyper-reflective foci (HRF) and (6) destruction or absence of the ellipsoid zone (EZ) and retinal pigment epithelium (RPE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Risk factors for m-CNV recurrence include a greater number of required injections, older age, large macular CNV, juxtafoveal location, increased HRF height and changes in EZ and RPE structure. Understanding these factors can inform personalised treatment approaches and improve patient outcomes by identifying individuals at higher risk of recurrence and implementing proactive measures to mitigate the impact of m-CNV recurrence and progression. Further investigation is needed to enhance our understanding of the underlying mechanisms and develop innovative therapeutic approaches for effective m-CNV management.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>CRD4202343461.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjophth-2023-001396","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T12:56:18Z","timestamp":1696942578000},"page":"e001396","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Recurrence risk of myopic choroidal neovascularisation: a systematic review of current study"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8618-1468","authenticated-orcid":false,"given":"Andi Arus","family":"Victor","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitalisa","family":"Andayani","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Djatikusumo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anggun Rama","family":"Yudantha","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Marbungaran","family":"Hutapea","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seruni Hanna","family":"Ardhia","sequence":"additional","affiliation":[{"name":"Research Assistant, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemal Akbar","family":"Suryoadji","sequence":"additional","affiliation":[{"name":"Research Assistant, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"2025090109142469000_8.1.e001396.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.09.004"},{"key":"2025090109142469000_8.1.e001396.2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-313308"},{"key":"2025090109142469000_8.1.e001396.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.08.010"},{"key":"2025090109142469000_8.1.e001396.4","doi-asserted-by":"crossref","first-page":"13700","DOI":"10.1038\/s41598-018-29536-x","article-title":"Patterns of posterior ocular complications in myopic eyes of Indian population","volume":"8","author":"Dhakal","year":"2018","journal-title":"Sci Rep"},{"key":"2025090109142469000_8.1.e001396.5","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-12795"},{"key":"2025090109142469000_8.1.e001396.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(84)34116-1"},{"key":"2025090109142469000_8.1.e001396.7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.survophthal.2014.10.002","article-title":"The other CNVM: a review of myopic choroidal neovascularization treatment in the age of anti-vascular endothelial growth factor agents","volume":"60","author":"Adatia","year":"2015","journal-title":"Surv Ophthalmol"},{"key":"2025090109142469000_8.1.e001396.8","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2147\/OPTH.S49437","article-title":"Current and emerging treatment options for myopic choroidal neovascularization","volume":"9","author":"El Matri","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"2025090109142469000_8.1.e001396.9","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305131"},{"key":"2025090109142469000_8.1.e001396.10","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181b1bb1a"},{"key":"2025090109142469000_8.1.e001396.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-011-1889-0"},{"key":"2025090109142469000_8.1.e001396.12","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.2147\/DDDT.S87920","article-title":"Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"2025090109142469000_8.1.e001396.13","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31827d260a"},{"key":"2025090109142469000_8.1.e001396.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227557","article-title":"Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: results from the LUMINOUS study","volume":"15","author":"Hamilton","year":"2020","journal-title":"PLoS One"},{"key":"2025090109142469000_8.1.e001396.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.10.023"},{"key":"2025090109142469000_8.1.e001396.16","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"},{"key":"2025090109142469000_8.1.e001396.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271342","article-title":"Incidence, predictors and re-treatment outcomes of recurrent myopic choroidal neovascularization","volume":"17","author":"Jain","year":"2022","journal-title":"PLoS One"},{"key":"2025090109142469000_8.1.e001396.18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/IAE.0000000000003673","article-title":"Risk factors of vision loss and multiple recurrences in myopic macular neovascularization","volume":"43","author":"Cicinelli","year":"2023","journal-title":"Retina"},{"key":"2025090109142469000_8.1.e001396.19","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.968800","article-title":"Factors associated with the recurrence of choroidal neovascularization in pathologic myopia","volume":"9","author":"Jing","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025090109142469000_8.1.e001396.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.08.002"},{"key":"2025090109142469000_8.1.e001396.21","first-page":"4951","article-title":"Factors associated with recurrent choroidal neovascularization due to pathological myopia treated with intravitreal anti-vascular endothelial growth factor injections","volume":"55","author":"Jo","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025090109142469000_8.1.e001396.22","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-318440"},{"key":"2025090109142469000_8.1.e001396.23","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1111\/aos.14893","article-title":"Vascular endothelial growth factor inhibitors for predominantly caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the fight retinal blindness! registry","volume":"100","author":"Gabrielle","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"2025090109142469000_8.1.e001396.24","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1097\/IAE.0000000000001384","article-title":"Choroidal thickness and chorioretinal atrophy in myopic choroidal neovascularization with anti-vascular endothelial growth factor therapy","volume":"37","author":"Lee","year":"2017","journal-title":"Retina"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2023-001396","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:14:34Z","timestamp":1756743274000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2023-001396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,10,10]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/bmjophth-2023-001396"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2023-001396","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}